Document is current
Any future updates will be listed below
-
Authors
Subramanian, Megha
McIninch, James https://orcid.org/0000-0002-9783-1251
Zlatev, Ivan https://orcid.org/0000-0003-2797-3032
Schlegel, Mark K. https://orcid.org/0000-0002-0127-608X
Kaittanis, Charalambos https://orcid.org/0000-0003-2137-5242
Nguyen, Tuyen
Agarwal, Saket https://orcid.org/0000-0002-1681-2842
Racie, Timothy
Alvarado, Martha Arbaiza
Wassarman, Kelly
Collins, Thomas S.
Chickering, Tyler
Brown, Christopher R.
Schmidt, Karyn
Castoreno, Adam B.
Shulga-Morskaya, Svetlana
Stamenova, Elena
Buckowing, Kira
Berman, Daniel https://orcid.org/0000-0002-0548-9744
Barry, Joseph D.
Bisbe, Anna
Maier, Martin A. https://orcid.org/0000-0002-4987-0184
Fitzgerald, Kevin
Jadhav, Vasant https://orcid.org/0000-0002-6666-0250
- License Information
-
More Information
Article History
Received: 11 November 2022
Accepted: 29 March 2023
First Online: 8 April 2023
Competing interests
: All authors were employees of Alnylam Pharmaceuticals with salary and/or stock options at the time the work was conducted. REVERSIR is a trademark of Alnylam Pharmaceuticals.
